Citations (104)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Po-Yi Paul Su, Lingyi Zhang, Liangliang He, Na Zhao & Zhonghui Guan. (2022) The Role of Neuro-Immune Interactions in Chronic Pain: Implications for Clinical Practice. Journal of Pain Research 15, pages 2223-2248.
Read now
Read now
Zhihao Liu, Mingjian Liu, Zhenqing Cao, Pengsen Qiu & Gaopeng Song. (2022) Phosphodiesterase‑4 inhibitors: a review of current developments (2013–2021). Expert Opinion on Therapeutic Patents 32:3, pages 261-278.
Read now
Read now
Sarah S Ch’Ng & Andrew J Lawrence. (2018) Investigational drugs for alcohol use disorders: a review of preclinical data. Expert Opinion on Investigational Drugs 27:5, pages 459-474.
Read now
Read now
Yuen H Kwok, James E Swift, Parisa Gazerani & Paul Rolan. (2016) A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine. Journal of Pain Research 9, pages 899-907.
Read now
Read now
Vikram Bhise & Suhayl Dhib-Jalbut. (2016) Further understanding of the immunopathology of multiple sclerosis: impact on future treatments. Expert Review of Clinical Immunology 12:10, pages 1069-1089.
Read now
Read now
Andrew D. Goodman, Tirisham Gyang & Andrew D. Smith$suffix/text()$suffix/text(). (2016) Ibudilast for the treatment of multiple sclerosis. Expert Opinion on Investigational Drugs 25:10, pages 1231-1237.
Read now
Read now
Articles from other publishers (98)
Letizia Crocetti, Maria Paola Giovannoni, Claudia Vergelli, Gabriella Guerrini, Fabrizio Melani & Agostino Cilibrizzi. (2024) New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration. Journal of Molecular Structure 1295, pages 136719.
Crossref
Crossref
Dimitrios C Ladakis, Maria I Reyes-Mantilla, Sachin P Gadani, Jackson W Mace, Susana C Dominguez-Penuela, Mayaa J Appiah, Matthew D Smith, Pavan Bhargava, Robert J Fox, Shiv Saidha & Peter A Calabresi. (2023) Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis. Multiple Sclerosis Journal.
Crossref
Crossref
Henrik Ehrhardt, Jeffrey LambeHussein MoussaEleni S. Vasileiou, Grigorios KalaitzidisOlwen C. Murphy, Angeliki G. Filippatou, Nicole PellegriniMorgan Douglas, Simidele DavisNatalia NagyAgustina QuirogaChen HuAlexandra Zambriczki LeeAnna DuvalKathryn C. Fitzgerald, Jerry L. PrincePeter A. Calabresi, Elias S. Sotirchos, Robert BermelShiv Saidha. (2023) Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes. Neurology 101:10.
Crossref
Crossref
Arushi Sandhu, Kajal Rawat, Vipasha Gautam, Antika Sharma, Anil Kumar & Lekha Saha. (2023) Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder. Brain Research 1815, pages 148443.
Crossref
Crossref
Baochan Du, Min Luo, Changyu Ren & Jifa Zhang. (2023) PDE4 inhibitors for disease therapy: advances and future perspective. Future Medicinal Chemistry.
Crossref
Crossref
Jian Jin, Francesca Mazzacuva, Letizia Crocetti, Maria Paola Giovannoni & Agostino Cilibrizzi. (2023) PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes. International Journal of Molecular Sciences 24:14, pages 11518.
Crossref
Crossref
Akram Sharifian, Jaleh Varshosaz, Mehdi Aliomrani & Mohammad Kazemi. (2023) Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model. International Journal of Pharmaceutics 638, pages 122936.
Crossref
Crossref
Wen-Qian Wu & Hua-Li Qin. (2023)
Synthesis of Pyrazolo[1,5-
a
]pyridinyl, Pyrazolo[1,5-
a
]quinolinyl, and Pyrazolo[5,1-
a
]isoquinolinyl Sulfonyl Fluorides via a [3 + 2] Annulation
. The Journal of Organic Chemistry 88:5, pages 3266-3276.
Crossref
Crossref
Benjamin Davies, Oliver D Mowforth, Stefan Yordanov, Daniel Alvarez-Berdugo, Simon Bond, Marianna Nodale, Paula Kareclas, Lynne Whitehead, Jon Bishop, Siddharthan Chandran, Sarah Lamb, Mark Bacon, Marios C Papadopoulos, Michelle Starkey, Iwan Sadler, Lara Smith, Sukhvinder Kalsi-Ryan, Adrian Carpenter, Rikin A Trivedi, Martin Wilby, David Choi, Ian B Wilkinson, Michael G Fehlings, Peter John Hutchinson & Mark R N Kotter. (2023) Targeting patient recovery priorities in degenerative cervical myelopathy: design and rationale for the RECEDE-Myelopathy trial—study protocol. BMJ Open 13:3, pages e061294.
Crossref
Crossref
Giovanni Oliveros, Charles H Wallace, Osama Chaudry, Qiao Liu, Yue Qiu, Lei Xie, Patricia Rockwell, Maria E Figueiredo-Pereira & Peter A Serrano. (2023) Repurposing ibudilast to mitigate Alzheimer’s disease by targeting inflammation. Brain 146:3, pages 898-911.
Crossref
Crossref
Efthalia Angelopoulou, Efstratios-Stylianos Pyrgelis & Christina Piperi. (2022) Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence. Molecules 27:23, pages 8448.
Crossref
Crossref
Hongjin Zhai, Shuo Zhang, Maxwell Ampomah-Wireko, Huanhuan Wang, Yaquan Cao, Pu Yang, Yingxue Yang, Firas Obald Arhema Frejat, Lihong Wang, Bingbing Zhao, Changzhong Ren & Chunli Wu. (2022) Pyrazole: An Important Core in Many Marketed and Clinical Drugs. Russian Journal of Bioorganic Chemistry 48:6, pages 1175-1189.
Crossref
Crossref
Igor Philippov, Yuriy Gatilov, Alina Sonina & Aleksey Vorob’ev. (2022) Oxidative [3+2]Cycloaddition of Alkynylphosphonates with Heterocyclic N-Imines: Synthesis of Pyrazolo[1,5-a]Pyridine-3-phosphonates. Molecules 27:22, pages 7913.
Crossref
Crossref
Krishnamoorthi Sumaiya, Panneerselvam Selvambika & Kalimuthusamy Natarajaseenivasan. (2022) Anti-macrophage migration inhibitory factor (MIF) activity of ibudilast: A repurposing drug attenuates the pathophysiology of leptospirosis. Microbial Pathogenesis, pages 105786.
Crossref
Crossref
Letizia Crocetti, Giuseppe Floresta, Agostino Cilibrizzi & Maria Paola Giovannoni. (2022) An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022. Molecules 27:15, pages 4964.
Crossref
Crossref
Wei Zhang, Ryosuke Matsukane, Nobuaki Egashira, Yuichi Tsuchiya, Rao Fu, Shota Yamamoto, Takeshi Hirota & Ichiro Ieiri. (2022) Neuroprotective effects of ibudilast against tacrolimus induced neurotoxicity. Toxicology and Applied Pharmacology 449, pages 116112.
Crossref
Crossref
Raju Jannapu Reddy, Nunavath Sharadha & Arram Haritha Kumari. (2022)
Base-mediated [3 + 2]-cycloannulation strategy for the synthesis of pyrazolo[1,5-
a
]pyridine derivatives using (
E
)-β-iodovinyl sulfones
. Organic & Biomolecular Chemistry 20:21, pages 4331-4337.
Crossref
Crossref
Thaddeus M. Barney, Andrew S. Vore & Terrence Deak. (2022) Acute Ethanol Challenge Differentially Regulates Expression of Growth Factors and miRNA Expression Profile of Whole Tissue of the Dorsal Hippocampus. Frontiers in Neuroscience 16.
Crossref
Crossref
Luciana Rigoli, Valerio Caruso, Giuseppina Salzano & Fortunato Lombardo. (2022) Wolfram Syndrome 1: From Genetics to Therapy. International Journal of Environmental Research and Public Health 19:6, pages 3225.
Crossref
Crossref
Aref-Ali Gharooni, Brian K. Kwon, Michael G. Fehlings, Timothy F. Boerger, Ricardo Rodrigues-Pinto, Paul Aarne Koljonen, Shekar N. Kurpad, James S. Harrop, Bizhan Aarabi, Vafa Rahimi-Movaghar, Jefferson R. Wilson, Benjamin M. Davies, Mark R. N. Kotter & James D. Guest. (2022) Developing Novel Therapies for Degenerative Cervical Myelopathy [AO Spine RECODE-DCM Research Priority Number 7]: Opportunities From Restorative Neurobiology. Global Spine Journal 12:1_suppl, pages 109S-121S.
Crossref
Crossref
Swati Dhasmana, Anupam Dhasmana, Acharan S. Narula, Meena Jaggi, Murali M. Yallapu & Subhash C. Chauhan. (2022) The panoramic view of amyotrophic lateral sclerosis: A fatal intricate neurological disorder. Life Sciences 288, pages 120156.
Crossref
Crossref
Robert J Fox, Paola Raska, Christian Barro, Matthew Karafa, Victoria Konig, Robert A Bermel, Marianne Chase, Christopher S Coffey, Andrew D Goodman, Eric C Klawiter, Robert T Naismith & Jens Kuhle. (2021) Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. Multiple Sclerosis Journal 27:13, pages 2014-2022.
Crossref
Crossref
Nobuaki Egashira, Yu Goto, Ryota Takahashi, Hikari Iba, Shota Yamamoto, Takuya Watanabe, Kaori Kubota, Takehiro Kawashiri, Chise Taniguchi, Shutaro Katsurabayashi & Katsunori Iwasaki. (2021) Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats. Journal of Pharmacological Sciences 147:1, pages 114-117.
Crossref
Crossref
Jiyun Sun, Zhiwei Xiao, Ahmed Haider, Catherine Gebhard, Hao Xu, Hai-Bin Luo, Han-Ting Zhang, Lee Josephson, Lu Wang & Steven H. Liang. (2021) Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery. Journal of Medicinal Chemistry 64:11, pages 7083-7109.
Crossref
Crossref
Xue Li, Yu Zou, Yuan-Yuan Fu, Jia Xing, Kai-Yue Wang, Peng-Zhi Wan, Mo Wang & Xiao-Yue Zhai. (2021) Ibudilast Attenuates Folic Acid–Induced Acute Kidney Injury by Blocking Pyroptosis Through TLR4-Mediated NF-κB and MAPK Signaling Pathways. Frontiers in Pharmacology 12.
Crossref
Crossref
Veronika Furlan & Urban Bren. (2021) Insight into Inhibitory Mechanism of PDE4D by Dietary Polyphenols Using Molecular Dynamics Simulations and Free Energy Calculations. Biomolecules 11:3, pages 479.
Crossref
Crossref
Nathalia Fonseca Nadur, Luciana Luiz de Azevedo, Lucas Caruso, Cedric Stephan Graebin, Renata Barbosa Lacerda & Arthur Eugen Kümmerle. (2021) The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure. European Journal of Medicinal Chemistry 212, pages 113123.
Crossref
Crossref
Ting Peng, Baowen Qi, Jun He, Hengming Ke & Jianyou Shi. (2020) Advances in the Development of Phosphodiesterase-4 Inhibitors. Journal of Medicinal Chemistry 63:19, pages 10594-10617.
Crossref
Crossref
Tom T Fischer & Barbara E Ehrlich. (2020) Wolfram syndrome: a monogenic model for diabetes mellitus and neurodegeneration. Current Opinion in Physiology 17, pages 115-123.
Crossref
Crossref
Christina Teng, Stephanie E. Reuter, Prunella L. Blinman, Haryana M. Dhillon, Peter Galettis, Nicholas Proschogo, Andrew J. McLachlan & Janette L. Vardy. (2020) Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer. Cancer Chemotherapy and Pharmacology 86:4, pages 547-558.
Crossref
Crossref
Pablo Berríos-Cárcamo, Mauricio Quezada, María Elena Quintanilla, Paola Morales, Marcelo Ezquer, Mario Herrera-Marschitz, Yedy Israel & Fernando Ezquer. (2020) Oxidative Stress and Neuroinflammation as a Pivot in Drug Abuse. A Focus on the Therapeutic Potential of Antioxidant and Anti-Inflammatory Agents and Biomolecules. Antioxidants 9:9, pages 830.
Crossref
Crossref
Lien D. Nguyen, Tom T. Fischer, Damien AbreuAlfredo ArroyoFumihiko Urano & Barbara E. Ehrlich. (2020) Calpain inhibitor and ibudilast rescue β cell functions in a cellular model of Wolfram syndrome. Proceedings of the National Academy of Sciences 117:29, pages 17389-17398.
Crossref
Crossref
Sabina V. Alieva & Aleksey Yu. Vorob’ev. (2020) Synthesis of 3-Fluoropyrazolo[1,5-A]Pyridines by Fluorination of Methyl Pyrazolo[1,5-A]Pyridine-3-Carboxylates. Chemistry of Heterocyclic Compounds 56:7, pages 957-960.
Crossref
Crossref
Tyler J. Alban, Defne Bayik, Balint Otvos, Anja Rabljenovic, Lin Leng, Leu Jia-Shiun, Gustavo Roversi, Adam Lauko, Arbaz A. Momin, Alireza M. Mohammadi, David M. Peereboom, Manmeet S. Ahluwalia, Kazuko Matsuda, Kyuson Yun, Richard Bucala, Michael A. Vogelbaum & Justin D. Lathia. (2020) Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression. Frontiers in Immunology 11.
Crossref
Crossref
Keith G. Heinzerling, Marisa Briones, April D. Thames, Charles H. Hinkin, Tianle Zhu, Ying Nian Wu & Steven J. Shoptaw. (2019) Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder. Journal of Neuroimmune Pharmacology 15:2, pages 238-248.
Crossref
Crossref
Jessica SY Lim & Peter CA Kam. (2020) Neuroimmune mechanisms of pain: Basic science and potential therapeutic modulators. Anaesthesia and Intensive Care 48:3, pages 167-178.
Crossref
Crossref
Michael J. Li, Marisa S. Briones, Keith G. Heinzerling, Mariah M. Kalmin & Steven J. Shoptaw. (2020) Ibudilast attenuates peripheral inflammatory effects of methamphetamine in patients with methamphetamine use disorder. Drug and Alcohol Dependence 206, pages 107776.
Crossref
Crossref
Parisa Gazerani. (2019) Identification of novel analgesics through a drug repurposing strategy. Pain Management 9:4, pages 399-415.
Crossref
Crossref
Felix I. L. Clanchy & Richard O. Williams. (2019) Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis. Arthritis & Rheumatology 71:5, pages 703-711.
Crossref
Crossref
Jennifer K. Melbourne, K. Ryan Thompson, Hui Peng & Kimberly Nixon. 2019. Molecular Basis of Neuropsychiatric Disorders: from Bench to Bedside. Molecular Basis of Neuropsychiatric Disorders: from Bench to Bedside
179
221
.
Gregory Powell, Erin A. McClure, M. Foster Olive & Cassandra D. Gipson. 2019. The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine. The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine
219
233
.
Elizabeth A Mills, Joel A Begay, Caitlyn Fisher & Yang Mao-Draayer. (2018) Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS. Multiple Sclerosis Journal 24:14, pages 1795-1807.
Crossref
Crossref
David Borsook, Andrew M. Youssef, Laura Simons, Igor Elman & Christopher Eccleston. (2018) When pain gets stuck: the evolution of pain chronification and treatment resistance. Pain 159:12, pages 2421-2436.
Crossref
Crossref
Hermann A.M. Mucke. (2018) Drug Repurposing Patent Applications April–June 2018. ASSAY and Drug Development Technologies 16:7, pages 420-426.
Crossref
Crossref
Floriana De Angelis, Domenico Plantone & Jeremy Chataway. (2018) Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. CNS Drugs 32:6, pages 499-526.
Crossref
Crossref
Sebastiano Giuseppe Crisafulli, Simona Brajkovic, Maria Sara Cipolat Mis, Valeria Parente & Stefania Corti. (2017) Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis. Molecular Neurobiology 55:4, pages 2789-2813.
Crossref
Crossref
Jonathan Jia Yuan Ong, Diana Yi-Ting Wei & Peter J. Goadsby. (2018) Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs 78:4, pages 411-437.
Crossref
Crossref
Z.D. Cooper, K.W. Johnson, S.K. Vosburg, M.A. Sullivan, J. Manubay, D. Martinez, J.D. Jones, P.A. Saccone & S.D. Comer. (2017) Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers. Drug and Alcohol Dependence 178, pages 340-347.
Crossref
Crossref
Ian N. Johnston, Manuela Tan, Jacob Cao, Antigone Matsos, Daniel R.L. Forrest, Emily Si, Joanna E. Fardell & Mark R. Hutchinson. (2017) Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive impairments in rats. Behavioural Brain Research 334, pages 109-118.
Crossref
Crossref
Joanna Schwenkgrub, Malgorzata Zaremba, Ilona Joniec-Maciejak, Agnieszka Cudna, Dagmara Mirowska-Guzel & Iwona Kurkowska-Jastrzębska. (2017) The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson’s disease. PLOS ONE 12:7, pages e0182019.
Crossref
Crossref
Julie Wieseler, Amanda Ellis, Andrew McFadden, Kendra Stone, Kimberley Brown, Sara Cady, Leandro F. Bastos, David Sprunger, Niloofar Rezvani, Kirk Johnson, Kenner C. Rice, Steven F. Maier & Linda R. Watkins. (2017) Supradural inflammatory soup in awake and freely moving rats induces facial allodynia that is blocked by putative immune modulators. Brain Research 1664, pages 87-94.
Crossref
Crossref
Aleksey Yu Vorob’ev, Vyacheslav I Supranovich, Gennady I Borodkin & Vyacheslav G Shubin. (2017)
New approach toward the synthesis of deuterated pyrazolo[1,5-
a
]pyridines and 1,2,4-triazolo[1,5-
a
]pyridines
. Beilstein Journal of Organic Chemistry 13, pages 800-805.
Crossref
Crossref
Jorge L. Cueva Vargas, Nicolas Belforte & Adriana Di Polo. (2016) The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling. Neurobiology of Disease 93, pages 156-171.
Crossref
Crossref
Robert J. Fox, Christopher S. Coffey, Merit E. Cudkowicz, Trevis Gleason, Andrew Goodman, Eric C. Klawiter, Kazuko Matsuda, Michelle McGovern, Robin Conwit, Robert Naismith, Akshata Ashokkumar, Robert Bermel, Dixie Ecklund, Maxine Koepp, Jeffrey Long, Sneha Natarajan, Srividya Ramachandran, Thomai Skaramagas, Brenda Thornell, Jon Yankey, Mark Agius, Khurram Bashir, Bruce Cohen, Patricia Coyle, Silvia Delgado, Dana Dewitt, Angela Flores, Barbara Giesser, Myla Goldman, Burk Jubelt, Neil Lava, Sharon Lynch, Augusto Miravalle, Harold Moses, Daniel Ontaneda, Jai Perumal, Michael Racke, Pavle Repovic, Claire Riley, Christopher Severson, Shlomo Shinnar, Valerie Suski, Bianca Weinstock-Gutman, Vijayshree Yadav & Aram Zabeti. (2016) Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemporary Clinical Trials 50, pages 166-177.
Crossref
Crossref
Dustin Z. DeYoungKeith G. HeinzerlingAimee-Noelle SwansonJohn TsuangBenjamin A. FurstYi YiYing Nian WuDavid E. MoodyDavid M. AndrenyakSteven J. Shoptaw. (2016) Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment. Journal of Clinical Psychopharmacology 36:4, pages 347-354.
Crossref
Crossref
M. D. Scofield, J. A. Heinsbroek, C. D. Gipson, Y. M. Kupchik, S. Spencer, A. C. W. Smith, D. Roberts-Wolfe & P. W. Kalivas. (2016) The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis. Pharmacological Reviews 68:3, pages 816-871.
Crossref
Crossref
Ziva D. Cooper, Kirk W. Johnson, Martina Pavlicova, Andrew Glass, Suzanne K. Vosburg, Maria A. Sullivan, Jeanne M. Manubay, Diana M. Martinez, Jermaine D. Jones, Phillip A. Saccone & Sandra D. Comer. (2016) The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addiction Biology 21:4, pages 895-903.
Crossref
Crossref
Matthias Bros, Evelyn Montermann, Anna Cholaszczyńska & Angelika B. Reske-Kunz. (2016) The phosphodiesterase 4 inhibitor roflumilast augments the Th17-promoting capability of dendritic cells by enhancing IL-23 production, and impairs their T cell stimulatory activity due to elevated IL-10. International Immunopharmacology 35, pages 174-184.
Crossref
Crossref
Daniel Ruiz-PérezJavier BenitoGonzalo PoloCarlota LargoDelia AguadoLuis SanzIgnacio A. Gómez de Segura. (2016) The Effects of the Toll-Like Receptor 4 Antagonist, Ibudilast, on Sevoflurane’s Minimum Alveolar Concentration and the Delayed Remifentanil-Induced Increase in the Minimum Alveolar Concentration in Rats. Anesthesia & Analgesia 122:5, pages 1370-1376.
Crossref
Crossref
Martin F. Bjurstrom, Sarah E. Giron & Charles A. Griffis. (2016) Cerebrospinal Fluid Cytokines and Neurotrophic Factors in Human Chronic Pain Populations: A Comprehensive Review. Pain Practice 16:2, pages 183-203.
Crossref
Crossref
Amy W. Voigt & Harry J. GouldIIIIII. (2016) Chronic Daily Headache: Mechanisms and Principles of Management. Current Pain and Headache Reports 20:2.
Crossref
Crossref
T.J. Phillips, J.R.K. Mootz & C. Reed. 2016. Animal Models for Medications Screening to Treat Addiction. Animal Models for Medications Screening to Treat Addiction
39
85
.
Geoffrey Littlejohn. (2015) Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome. Nature Reviews Rheumatology 11:11, pages 639-648.
Crossref
Crossref
Pierluca Coiro, Ragunathan Padmashri, Anand Suresh, Elizabeth Spartz, Gurudutt Pendyala, Shinnyi Chou, Yoosun Jung, Brittney Meays, Shreya Roy, Nagsen Gautam, Yazen Alnouti, Ming Li & Anna Dunaevsky. (2015) Impaired synaptic development in a maternal immune activation mouse model of neurodevelopmental disorders. Brain, Behavior, and Immunity 50, pages 249-258.
Crossref
Crossref
Jacinta L. Johnson, Yuen H. Kwok, Nicole M. Sumracki, James E. Swift, Mark R. Hutchinson, Kirk Johnson, Desmond B. Williams, Jonathon Tuke & Paul E. Rolan. (2015) Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety. Headache: The Journal of Head and Face Pain 55:9, pages 1192-1208.
Crossref
Crossref
Sarah E. Giron, Charles A. Griffis & Joseph F. Burkard. (2015) Chronic Pain and Decreased Opioid Efficacy: An Inflammatory Link. Pain Management Nursing 16:5, pages 819-831.
Crossref
Crossref
Hans-Christoph Diener, Andrew Charles, Peter J Goadsby & Dagny Holle. (2015) New therapeutic approaches for the prevention and treatment of migraine. The Lancet Neurology 14:10, pages 1010-1022.
Crossref
Crossref
Samir K. Ballas. (2015) Pathophysiology and principles of management of the many faces of the acute vaso-occlusive crisis in patients with sickle cell disease. European Journal of Haematology 95:2, pages 113-123.
Crossref
Crossref
Caroline A. Arout, Ellen Edens, Ismene L. Petrakis & Mehmet Sofuoglu. (2015) Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations. CNS Drugs 29:6, pages 465-486.
Crossref
Crossref
Hanna M. Vesterinen, Peter Connick, Cadi M. J. Irvine, Emily S. Sena, Kieren J. Egan, Gary G. Carmichael, Afiyah Tariq, Sue Pavitt, Jeremy Chataway, Malcolm R. Macleod & Siddharthan Chandran. (2015) Drug Repurposing: A Systematic Approach to Evaluate Candidate Oral Neuroprotective Interventions for Secondary Progressive Multiple Sclerosis. PLOS ONE 10:4, pages e0117705.
Crossref
Crossref
Richard L. Bell, Marcelo F. Lopez, Changhai Cui, Mark Egli, Kirk W. Johnson, Kelle M. Franklin & Howard C. Becker. (2015) Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addiction Biology 20:1, pages 38-42.
Crossref
Crossref
Michael D. Scofield & Peter W. Kalivas. (2014) Astrocytic Dysfunction and Addiction. The Neuroscientist 20:6, pages 610-622.
Crossref
Crossref
J L Johnson, P E Rolan, M E Johnson, L Bobrovskaya, D B Williams, K Johnson, J Tuke & M R Hutchinson. (2014) Codeine-induced hyperalgesia and allodynia: investigating the role of glial activation. Translational Psychiatry 4:11, pages e482-e482.
Crossref
Crossref
Hao Wang, Zhen lin Mei, Kai Long Zhong, Mei Hu, Yan Long, Ming Xing Miao, Ning Li, Tian Hua Yan & Hao Hong. (2014) Pretreatment with antiasthmatic drug ibudilast ameliorates Aβ1–42-induced memory impairment and neurotoxicity in mice. Pharmacology Biochemistry and Behavior 124, pages 373-379.
Crossref
Crossref
Vinod Tiwari, Yun Guan & Srinivasa N. Raja. (2014) Modulating the delicate glial–neuronal interactions in neuropathic pain: Promises and potential caveats. Neuroscience & Biobehavioral Reviews 45, pages 19-27.
Crossref
Crossref
Nazira El-Hage, Myosotys Rodriguez, Elizabeth M. Podhaizer, Shiping Zou, Seth M. Dever, Sarah E. Snider, Pamela E. Knapp, Patrick M. Beardsley & Kurt F. Hauser. (2014) Ibudilast (AV411), and its AV1013 analog, reduce HIV-1 replication and neuronal death induced by HIV-1 and morphine. AIDS 28:10, pages 1409-1419.
Crossref
Crossref
Peter M. Grace, Mark R. Hutchinson, Steven F. Maier & Linda R. Watkins. (2014) Pathological pain and the neuroimmune interface. Nature Reviews Immunology 14:4, pages 217-231.
Crossref
Crossref
Amanda Ellis, Julie Wieseler, Jacob Favret, Kirk W. Johnson, Kenner C. Rice, Steven F. Maier, Scott Falci & Linda R. Watkins. (2014) Systemic Administration of Propentofylline, Ibudilast, and (+)-Naltrexone Each Reverses Mechanical Allodynia in a Novel Rat Model of Central Neuropathic Pain. The Journal of Pain 15:4, pages 407-421.
Crossref
Crossref
Matthew J. Robson, Ryan C. Turner, Zachary J. Naser, Christopher R. McCurdy, James P. O'Callaghan, Jason D. Huber & Rae R. Matsumoto. (2014) SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. Experimental Neurology 254, pages 180-189.
Crossref
Crossref
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki. (2014) Ibudilast for the treatment of drug addiction and other neurological conditions. Clinical Investigation 4:3, pages 269-279.
Crossref
Crossref
Krista M. RodgersYuetiva K. DemingFlorencia M. BercumSerhiy Y. ChumachenkoJulie L. WieselerKirk W. JohnsonLinda R. WatkinsDaniel S. Barth. (2014) Reversal of Established Traumatic Brain Injury-Induced, Anxiety-Like Behavior in Rats after Delayed, Post-Injury Neuroimmune Suppression. Journal of Neurotrauma 31:5, pages 487-497.
Crossref
Crossref
Paula Pifarré, María Gutierrez-Mecinas, Judith Prado, Lorena Usero, Carme Roura-Mir, Mercedes Giralt, Juan Hidalgo & Agustina García. (2014) Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions. Experimental Neurology 251, pages 58-71.
Crossref
Crossref
Lara A. Ray, Daniel J.O. Roche, Keith Heinzerling & Steve Shoptaw. 2014. Neuroimmune Signaling in Drug Actions and Addictions. Neuroimmune Signaling in Drug Actions and Addictions
381
401
.
Leandro Francisco Silva Bastos & Márcio Matos Coelho. (2013) Drug Repositioning: Playing Dirty to Kill Pain. CNS Drugs 28:1, pages 45-61.
Crossref
Crossref
Joanna Mika, Magdalena Zychowska, Katarzyna Popiolek-Barczyk, Ewelina Rojewska & Barbara Przewlocka. (2013) Importance of glial activation in neuropathic pain. European Journal of Pharmacology 716:1-3, pages 106-119.
Crossref
Crossref
Pradeep Chopra & Mark S. Cooper. (2013) Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN). Journal of Neuroimmune Pharmacology 8:3, pages 470-476.
Crossref
Crossref
Sarah E. Snider, Elizabeth S. Hendrick & Patrick M. Beardsley. (2013) Glial cell modulators attenuate methamphetamine self-administration in therat. European Journal of Pharmacology 701:1-3, pages 124-130.
Crossref
Crossref
Jacinta L Johnson, Mark R Hutchinson, Desmond B Williams & Paul Rolan. (2012) Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia 33:1, pages 52-64.
Crossref
Crossref
Yue Wu & Mark R. Hutchinson. 2013. Neural-Immune Interactions in Brain Function and Alcohol Related Disorders. Neural-Immune Interactions in Brain Function and Alcohol Related Disorders
535
559
.
Ryan Jalleh, Keith Koh, Boyoun Choi, Ebony Liu, John Maddison & Mark R. Hutchinson. (2012) Role of microglia and toll-like receptor 4 in the pathophysiology of delirium. Medical Hypotheses 79:6, pages 735-739.
Crossref
Crossref
Yuqiang Shi, Benjamin B. Gelman, Joshua G. Lisinicchia & Shao-Jun Tang. (2012) Chronic-Pain-Associated Astrocytic Reaction in the Spinal Cord Dorsal Horn of Human Immunodeficiency Virus-Infected Patients. The Journal of Neuroscience 32:32, pages 10833-10840.
Crossref
Crossref
Krista M. RodgersFlorencia M. BercumDanielle L. McCallumJerry W. RudyLauren C. FreyKirk W. JohnsonLinda R. WatkinsDaniel S. Barth. (2012) Acute Neuroimmune Modulation Attenuates the Development of Anxiety-Like Freezing Behavior in an Animal Model of Traumatic Brain Injury. Journal of Neurotrauma 29:10, pages 1886-1897.
Crossref
Crossref
Jaclyn M. Schwarz, Mark R. Hutchinson & Staci D. Bilbo. (2011) Early-Life Experience Decreases Drug-Induced Reinstatement of Morphine CPP in Adulthood via Microglial-Specific Epigenetic Programming of Anti-Inflammatory IL-10 Expression. The Journal of Neuroscience 31:49, pages 17835-17847.
Crossref
Crossref
Michelle Kiebala & Sanjay B. Maggirwar. (2011) Ibudilast, a Pharmacologic Phosphodiesterase Inhibitor, Prevents Human Immunodeficiency Virus-1 Tat-Mediated Activation of Microglial Cells. PLoS ONE 6:4, pages e18633.
Crossref
Crossref
Hermann Tenor, Armin Hatzelmann, Rolf Beume, Gezim Lahu, Karl Zech & Thomas D. Bethke. 2011. Phosphodiesterases as Drug Targets. Phosphodiesterases as Drug Targets
85
119
.
Mark A. Giembycz & Robert Newton. 2011. Phosphodiesterases as Drug Targets. Phosphodiesterases as Drug Targets
415
446
.
Gillian Burgess & Dic Williams. (2010) The discovery and development of analgesics: new mechanisms, new modalities. Journal of Clinical Investigation 120:11, pages 3753-3759.
Crossref
Crossref
Patrick M. Beardsley, Keith L. Shelton, Elizabeth Hendrick & Kirk W. Johnson. (2010) The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse. European Journal of Pharmacology 637:1-3, pages 102-108.
Crossref
Crossref